Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
about
Body composition changes in females treated for breast cancer: a review of the evidenceTamoxifen reduces fat mass by boosting reactive oxygen speciesThe muscle mass, omega-3, diet, exercise and lifestyle (MODEL) study - a randomised controlled trial for women who have completed breast cancer treatment.Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors.The impact of a cancer diagnosis on weight change: findings from prospective, population-based cohorts in the UK and the USThe impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study.A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab.Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.Exemestane in the prevention settingThe patient experienceSafety of aromatase inhibitors in the adjuvant setting.Aromatase inhibitors and calcium absorption in early stage breast cancer.Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyComparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.Weight management and its role in breast cancer rehabilitation.Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudyAdjuvant treatment of breast cancer in postmenopausal women: role of exemestane.Muscle function and omega-3 fatty acids in the prediction of lean body mass after breast cancer treatment.Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.A prospective model of care for breast cancer rehabilitation: bone health and arthralgias.Design of a Mestranol 2-N-Piperazino-Substituted Derivative Showing Potent and Selective in vitro and in vivo Activities in MCF-7 Breast Cancer Models.Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?Physical activity and body composition, body physique, and quality of life in premenopausal breast cancer patients during endocrine therapy--a feasibility study.Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed?The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors.Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
P2860
Q27004662-DDC64246-8EAC-4259-8190-245B75D6B403Q30370538-8DAF1A1A-A920-4F07-865E-B5DF81582C18Q33552584-2E62294D-856B-46B9-AE46-9E5216036BA6Q34022790-D110D4D7-0CFC-47DD-AD62-0494EBA46F4AQ34695540-4C5BAE4B-105B-4306-8952-CB2DAADD25DDQ35012609-21639037-A847-4523-AE5F-DCAFAE46E663Q35053866-B76C9010-073B-40A5-99C0-4638170E3189Q35195086-3B95BB43-58D6-4708-894C-6FEB2E26393DQ35842073-CCAD95BB-750F-4765-8702-7B5D0BEE5AFAQ35949285-BA290811-071D-4492-A1E9-C90F9AC52890Q36026414-403FC8D8-5B2A-42BA-B7AD-304087BE92E4Q36026543-DAF5E95C-74DB-46E1-8663-A05200361B5CQ36037270-4402EC57-E45E-4EE1-8EF9-42C936395307Q36693164-F253E70C-0ABA-4E2D-BD65-DEEF80C53C90Q36740503-B542CB4B-6E52-4187-9487-D90EBC299CDBQ37193002-410B697B-AB2D-4C56-80A7-40EA9C5B1AA1Q37267393-70996856-90E1-48C8-910A-6DB2BA6ABBEAQ37277165-3841796F-B442-4967-9195-372516E39645Q37355561-BDCB3F27-B230-428A-AFA3-65EF2C5F2756Q37439648-11226003-1DC4-453B-8D77-F579BDA8AE56Q37827010-9AF62C23-5B6B-41A2-8DCB-2804CC997104Q37955223-5797C918-838F-4F4B-9ADD-8BC414EF39E5Q38001377-B54337A3-CC01-4F99-80EA-465B652DB7D2Q38722671-EF679FC4-86FC-4ACA-8838-01BCBFEC6337Q38876325-3891B0AC-6169-4FE7-BFFB-EEA6CB9CDE54Q43493964-5BAE8510-2914-4F03-8935-5CF51C175BDBQ47187808-75EA50E5-028A-4A81-9A86-D009EB3F23A5Q47309977-BAFE86E7-EBAB-4F0A-809F-3EF1573F3107Q51590037-F2F5331A-1332-4776-BC31-EF19CFA216DBQ53608272-364186CB-066F-4D66-AF0E-888C3EE1C253Q55090991-621F2EC0-682B-4B7C-B305-5852E3A60F57
P2860
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Exemestane after tamoxifen as ...... n body composition and lipids.
@ast
Exemestane after tamoxifen as ...... n body composition and lipids.
@en
type
label
Exemestane after tamoxifen as ...... n body composition and lipids.
@ast
Exemestane after tamoxifen as ...... n body composition and lipids.
@en
prefLabel
Exemestane after tamoxifen as ...... n body composition and lipids.
@ast
Exemestane after tamoxifen as ...... n body composition and lipids.
@en
P2093
P2860
P356
P1476
Exemestane after tamoxifen as ...... n body composition and lipids.
@en
P2093
A Montagnani
E Francini
G Francini
R Petrioli
S Campagna
S Gonnelli
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603258
P407
P577
2006-07-01T00:00:00Z